667463-82-3
Chemical Structure
Indirubin-3′-oxime
Synonym(s): IDR3O; I3O
- CAS No.: 667463-82-3
- Formula:C16H11N3O2
- Molecular Weight:277.28
IUPAC Name: (2Z,3E)-3-(hydroxyimino)-[2,3'-biindolinylidene]-2'-one
InChIKey: HBDSHCUSXQATPO-BGBJRWHRSA-N
SMILES: O/N=C1C2=C(C=CC=C2)NC\1=C3C4=C(C=CC=C4)NC\3=O
Biological Activity: Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Indirubin-3′-oxime | 99.10% | Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xie Y, et al. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett. 2004;367(3):355-359. [Content Brief]
- [2]. Hu S, et al. Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β. J Mol Neurosci. 2015;57(4):561-570. [Content Brief]
- [3]. Choi S, et al. Indirubin-3'-oxime stimulates chondrocyte maturation and longitudinal bone growth via activation of the Wnt/β-catenin pathway. Exp Mol Med. 2019;51(9):1-10. Published 2019 Sep 12. [Content Brief]
